☆ 4.6 Letter

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

AMERICAN JOURNAL OF HEMATOLOGY (2013)

期刊

AMERICAN JOURNAL OF HEMATOLOGY

卷 88, 期 8, 页码 719-720

出版社

WILEY-BLACKWELL

DOI: 10.1002/ajh.23470

关键词

-

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Nicola Polverelli, Elena M. Elli, Elisabetta Abruzzese, Giuseppe A. Palumbo, Giulia Benevolo, Mario Tiribelli, Massimiliano Bonifacio, Alessia Tieghi, Giovanni Caocci, Mariella D'Adda, Micaela Bergamaschi, Gianni Binotto, Florian H. Heidel, Francesco Cavazzini, Monica Crugnola, Novella Pugliese, Costanza Bosi, Alessandro Isidori, Daniela Bartoletti, Giuseppe Auteri, Roberto Latagliata, Lisa Gandolfi, Bruno Martino, Luigi Scaffidi, Daniele Cattaneo, Fabio D'Amore, Malgorzata M. Trawinska, Rossella Stella, Uros Markovic, Lucia Catani, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Massimo Breccia, Domenico Russo, Michele Cavo, Alessandra Iurlo, Francesca Palandri

Summary: RUX treatment has been associated with a higher incidence of SPMs, with NMSCs being the most common. Risk factors for SPMs include male sex and thrombocytosis at RUX start. For SPMs excluding NMSCs, male sex, thrombocytosis, and previous arterial thromboses are considered high-risk factors.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Risk and outcome of second primary malignancy in patients with classical Hodgkin lymphoma

Fan Wang

Summary: Hodgkin lymphoma survivors have a significantly increased risk of developing secondary primary malignancies (SPMs). The overall survival is worse for cHL patients with SPMs, and SPMs are an independent prognostic factor for cHL.

MEDICINE (2022)

添加到收藏夹

Article Hematology

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Raphael E. Szalat, Joshua Gustine, J. Mark Sloan, Camille Edwards, Vaishali Sanchorawala

Summary: Daratumumab as a single agent or in combination with chemotherapies shows impressive efficacy in AL amyloidosis patients, but predictive factors associated with outcomes remain unclear. Achieving at least VGPR and presence of 1q21 gain are independently associated with better progression free survival and overall survival. Patients receiving more than 12 cycles of daratumumab therapy have significantly longer survival outcomes.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Review Hematology

Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

Kainat Saleem, Joseph Franz, Mary Lou Klem, Jonathan G. Yabes, Michael Boyiadzis, John R. Jones, Nader Shaikh, Konstantinos Lontos

Summary: This study conducted a systematic review and meta-analysis of the use of Lenalidomide in various disease settings. The findings suggest that Lenalidomide-induced second primary malignancies (SPM) occur exclusively in patients with multiple myeloma. There is no increased risk of SPM in other disease settings. Lenalidomide is an effective drug in the multiple myeloma setting, but patients should be monitored for both solid and hematological SPM.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

Jana Halamkova, Lucia Bohovicova, Lucie Pehalova, Roman Gonec, Teodor Stanek, Tomas Kazda, Lucie Moukova, Dagmar Adamkova Krakorova, Sarka Kozakova, Marek Svoboda, Regina Demlova, Igor Kiss

Summary: The association between hypolipidemic drugs and the occurrence of a second primary malignancy in colorectal cancer survivors is not clear. Subgroup analysis shows a lower incidence of secondary neoplasia in statin users, but colorectal cancer patients using hypolipidemic drugs are more likely to develop gastric and bladder cancer. Patients with early-stage colorectal carcinoma who suffered a second cancer have significantly worse survival outcomes if treated with hypolipidemic drugs. Therefore, screening for second primary malignancies in colorectal cancer survivors treated with hypolipidemic drugs should be done more cautiously, especially for gastric and bladder cancer.

CANCERS (2022)

添加到收藏夹

Article Oncology

Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018

Jing Wang, Chenglan Lv, Min Zhou, Jing-Yan Xu, Bing Chen, Yuan Wan

Summary: As survival times for multiple myeloma (MM) patients continue to extend, the risk of developing a second primary malignancy (SPM) among MM survivors is a growing concern. This study evaluated the risk and survival of SPM among MM survivors from 1975 to 2018 using the Surveillance, Epidemiology, and End Results (SEER) 9 Registry Database. Factors such as age, sex, race, and time of MM diagnosis were found to be associated with SPM occurrence. The study suggests the need for site- and time-specific surveillance strategies to monitor SPM in high-risk MM patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study

Utsav Joshi, Adheesh Bhattarai, Suman Gaire, Simrat Gill, Vishakha Agrawal, Sumeet Kumar Yadav, Soon Khai Low, Prajwal Dhakal, Vijaya Raj Bhatt, Peter A. Kouides

Summary: This study used a database to assess the risk of second primary malignancy (SPM) in patients with primary myelofibrosis (PMF). The findings indicate a higher risk of SPM in PMF patients and identify associated risk factors such as age, gender, treatment, and time of diagnosis.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Patients with Early-Onset Colorectal Cancer Have an Increased Risk of Second Primary Malignancy

Amelie Tiritilli, Cynthia Ko

Summary: Individuals with early-onset colorectal cancer (eoCRC) have a nearly 50% higher lifetime risk of second primary malignancy (SPM) compared to the general population. The risk of SPM is highest in the first 5 years after diagnosis and is increasing over time. The locations at highest risk for SPM after eoCRC include the small intestine, ureter, rectum, and colon.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer

Jiahui Yang, Fangli Wu, Hongjin An, Huatian Gan

Summary: This study aimed to investigate the incidence and risk factors for second primary malignancies among survivors diagnosed with colorectal cancer. The results showed that the most common sites of second primary malignancies were colorectal cancer, lung cancer, and bronchus cancer. Older age, male gender, married status, and localized stage of colorectal cancer were associated with a higher risk of second primary malignancies. Additionally, radiation therapy was found to increase the risk of second primary malignancies.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2023)

添加到收藏夹

Article Oncology

Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques

Edward Christopher Dee, Vinayak Muralidhar, Martin T. King, Neil E. Martin, Anthony D'Amico, Kent W. Mouw, Peter F. Orio, Paul L. Nguyen, Jonathan E. Leeman

Summary: Conventionally fractionated intensity-modulated radiotherapy, moderately hypofractionated intensity-modulated radiotherapy, and brachytherapy were associated with increased probability of a second malignancy compared to radical prostatectomy, while stereotactic body radiotherapy was not. Patients treated with SBRT may have a lower risk of second malignancy due to improved conformality, radiobiological differences, or patient selection.

RADIOTHERAPY AND ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Risk of second malignancy in patients with ovarian clear cell carcinoma

Julie My Van Nguyen, Danielle Vicus, Sharon Nofech-Mozes, Lilian T. Gien, Marcus Q. Bernardini, Marjan Rouzbahman, Liat Hogen

Summary: Patients with ovarian clear cell carcinoma are at increased risk of developing second primary malignancies, with the most common being breast, skin, and gastrointestinal tract cancers. Smoking and radiation therapy are associated with an increased risk of second primary malignancy. However, radiation therapy is not a significant risk factor for those developing second primary malignancies after ovarian clear cell carcinoma.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Oncology

Familial risk associated with lung cancer as a second primary malignancy in first-degree relatives

Jianguang Ji, Jan Sundquist, Kristina Sundquist, Guoqiao Zheng

Summary: This study found that the risk of lung cancer (LCa) is similar when a first-degree relative (FDR) is diagnosed with either LCa-1 or LCa-2. The risk is higher when the FDR is diagnosed with LCa-2 within a certain period of time after the first primary cancer. The risk of LCa is also increased for certain types of first primary cancers, such as ovarian, nervous system, upper aerodigestive tract, cervix, and non-Hodgkin lymphoma.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy-Who Is at the Greatest Risk?

Lily N. Trinh, Andrew R. Crawford, Mohammad H. Hussein, Mourad Zerfaoui, Eman A. Toraih, Gregory W. Randolph, Emad Kandil

Summary: This review identified a greater risk of developing second primary thyroid cancer (SPTC) in patients with primary breast, renal cell, basal cell, and ovarian cancers who are female and/or Caucasian. Surveillance protocols should be considered for these high-risk individuals.

CANCERS (2021)

添加到收藏夹

Article Medicine, General & Internal

Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

Liqing Guo, Yanpeng Fu, Chunyu Miao, Shuhong Wu, Yaqiong Zhu, Yuehui Liu

Summary: The study found an elevated risk of secondary primary malignancy in patients with hypopharyngeal carcinoma. Specific sites had higher risks, especially in the age group of 55-75 and all subgroups of sex, race, and latency. Patients with distant metastasis and those not undergoing surgery for the first tumor were associated with a significantly elevated risk of developing secondary primary malignancy.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

添加到收藏夹

Article Hematology

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up

Marco Basset, Christoph R. Kimmich, Nicholas Schreck, Julia Krzykalla, Tobias Dittrich, Kaya Veelken, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Carsten Mueller-Tidow, Axel Benner, Ute Hegenbart, Stefan O. Schoenland

Summary: In this retrospective study of 260 patients with RRAL, Lenalidomide and dexamethasone treatment showed a 3-month haematological response rate of 31%, with a median overall survival of 32 months. Factors such as VGHR and cardiac progression were found to impact prognosis during treatment, while baseline clonal and organ biomarkers could predict favorable outcomes.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

Ashutosh D. Wechalekar, M. Teresa Cibeira, Simon D. Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schonland, Christopher Venner, Mario Boccadoro, Efstathios Kastritis

Summary: This guideline recommends non-transplant chemotherapy treatment for AL amyloidosis patients, based on clinical presentation and patient tolerance. Targeted therapy evaluation and treatment methods for amyloid fibrils are urgently needed.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

添加到收藏夹

Article Hematology

Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice

Vaishali Sanchorawala, Ashutosh D. D. Wechalekar, Kihyun Kim, Stefan O. O. Schonland, Heather J. J. Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond L. L. Comenzo, Dasha Cherepanov, Vanessa C. C. Hayden, Arun Kumar, Richard Labotka, Douglas V. V. Faller, Efstathios Kastritis

Summary: Patient-reported outcomes in AL amyloidosis have not been thoroughly studied. However, analysis of data from the TOURMALINE-AL1 trial showed that patients treated with ixazomib-dexamethasone had similar or better health-related quality of life and symptoms compared to those treated with chemotherapy.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Review Hematology

Myelofibrosis

Francesco Passamonti, Barbara Mora

Summary: The clinical phenotype of myelofibrosis is characterized by splenomegaly, symptomatology, blood cell alterations, and vascular complications. Diagnosis requires evaluations of blood counts, bone marrow morphology, genetic mutations, and disease history. Treatment options include anemia-oriented therapies and JAK inhibitors, with stem cell transplant being the only curative option. New paradigms for evaluating efficacy and translational studies show promise for future strategies in MF patients.

BLOOD (2023)

添加到收藏夹

Article Hematology

Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi

Annalisa Arcari, Valentina Tabanelli, Francesco Merli, Luigi Marcheselli, Michele Merli, Monica Balzarotti, Vittorio Ruggero Zilioli, Alberto Fabbri, Federica Cavallo, Gloria Margiotta Casaluci, Alessandra Tucci, Benedetta Puccini, Elsa Pennese, Alice Di Rocco, Manuela Zanni, Leonardo Flenghi, Guido Gini, Roberto Sartori, Annalisa Chiappella, Sara Veronica Usai, Monica Tani, Dario Marino, Luca Arcaini, Daniele Vallisa, Michele Spina

Summary: Up to 10%-15% of DLBCL cases in elderly patients are related to HCV infection. HCV+ patients were older, less fit, and had frequent extranodal involvement compared to HCV- patients. The use of DAAs in HCV+ patients showed good tolerance and a positive impact on progression-free survival.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions

Lisa Mendelson, Tatiana Prokaeva, K. H. Vincent Lau, Vaishali Sanchorawala, Kristen McCausland, Brian Spencer, Surendra Dasari, Ellen D. McPhail, Michelle C. Kaku

Summary: This article describes the clinical features of hereditary gelsolin (AGel) amyloidosis, a systemic disease characterized by neurological, ophthalmological, dermatological, and other organ involvements. Neurological manifestations were observed in 15 patients, including cranial neuropathy, peripheral neuropathy, and carpal tunnel syndrome. A novel gelsolin variant was identified and associated with a unique clinical phenotype.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

添加到收藏夹

Article Oncology

Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

Maria E. Nizzoli, Martina Manni, Chiara Ghiggi, Alessandro Pulsoni, Gerardo Musuraca, Michele Merli, Catello Califano, Alessia Bari, Massimo Massaia, Annarita Conconi, Pellegrino Musto, Donato Mannina, Tommasina Perrone, Francesca Re, Sara Galimberti, Guido Gini, Monia Capponi, Umberto Vitolo, Sara V. Usai, Piero M. Stefani, Filippo Ballerini, Anna M. Liberati, Elsa Pennese, Domenico Pastore, Tetiana Skrypets, Hillary Catellani, Luigi Marcheselli, Massimo Federico, Stefano Luminari

Summary: We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different initial immunochemotherapy (ICT) regimens on patient outcomes. After a median of 56 months of follow-up, R-CHOP and RB had similar progression-free survival (PFS). Standard RM was associated with improved PFS compared to response-adapted management both after R-CHOP and RB. Grade 3-4 hematologic adverse events were more frequent with R-CHOP during induction treatment and more frequent with RB during RM.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli

Summary: Castleman disease (CD) is a rare lymphoproliferative disorder with various clinico-pathological subtypes. The pathogenesis of CD is still uncertain, but alterations in T-cell subsets may contribute to the development of CD. In this study, the distribution of T-cell subsets in the clinico-pathological spectrum of CD was investigated. The results showed decreased CD4/CD8 ratio and lower number of FOXP3+ T-reg cells in CD cases compared to non-specific reactive lymph nodes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Oncology

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-Garcia, Claire Harrison, Vikas Gupta

Summary: In patients with myelofibrosis who are naive to JAKi treatment, the rational combination of the BET inhibitor pelabresib and ruxolitinib showed good tolerability and durable improvements in spleen and symptom burden.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Hematology

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schoenland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Summary: The VITAL trial assessed the efficacy and safety of birtamimab in combination with standard of care in AL amyloidosis patients. Although no significant difference was observed in the overall results, a post hoc analysis showed significant improvement in survival time at month 9 for Mayo stage IV patients treated with birtamimab.

BLOOD (2023)

添加到收藏夹

Editorial Material Hematology

Deciphering molecular complexity of HCV-associated lymphoproliferation

Michele Merli, Francesco Passamonti, Luca Arcaini

Summary: Recent clinical studies have shown that patients with Hepatitis C virus-associated indolent lymphoproliferative disorders (LPD) can achieve lymphoma responses when treated solely with direct-acting antivirals (DAAs). However, the molecular mechanisms underlying LPD responses to DAAs are not well understood. In this paper, the authors provide new molecular insights, reporting intraclonal diversification and persistence of B-cell clones in most cases, even after viral eradication and positive clinical outcomes. These findings suggest that achieving a molecular response may not be necessary for a 'functional cure' in these patients. Further immunogenetic and mutational studies are needed to better understand this biological puzzle and refine treatment strategies.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Editorial Material Hematology

Early treatment for COVID-19 in patients with haematological malignancies: Much more than a recommendation!

Francesco Passamonti, Alessandra Bandera

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

Alessandra Carobbio, Alessandro Maria Vannucchi, Elisa Rumi, Valerio De Stefano, Alessandro Rambaldi, Giuseppe Carli, Maria Luigia Randi, Heinz Gisslinger, Francesco Passamonti, Juergen Thiele, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Article Oncology

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth

Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.

CANCERS (2023)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis

K. H. Vincent Lau, Tatiana Prokaeva, Luke Zheng, Gheorghe Doros, Michelle C. Kaku, Brian Spencer, John Berk, Vaishali Sanchorawala

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.